The efficacy of tobramycin in the treatment of ulcerative colitis.
This paper reports a double-blind placebo-controlled trial of oral tobramycin in acute ulcerative colitis. Eighty-four patients with an acute relapse of ulcerative colitis were randomized to receive oral tobramycin or placebo for 1 week as an adjunct to steroid therapy. At endpoint, 31 of 42 (74%) in the tobramycin group achieved complete symptomatic remission compared with 18 of 42 (43%) in the placebo group (P = 0.008). The tobramycin group achieved better histological scores (P less than 0.05) at endpoint. These findings show that treatment with oral tobramycin improves the short-term outcome of patients with ulcerative colitis in relapse.
Burke
D A
DA
Gastroenterology Unit, General Infirmary, Leeds, UK.
Axon
A T
AT
Clayden
S A
SA
Dixon
M F
MF
Johnston
D
D
Lacey
R W
RW
D000328:Adult; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014031:Tobramycin / Q000493:pharmacokinetics / Q000627:therapeutic use*
D014031:Tobramycin